FENOFIBRATE MICRO CAPSULE

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

FENOFIBRATE

Disponible des:

SANIS HEALTH INC

Codi ATC:

C10AB05

Designació comuna internacional (DCI):

FENOFIBRATE

Dosis:

200MG

formulario farmacéutico:

CAPSULE

Composición:

FENOFIBRATE 200MG

Vía de administración:

ORAL

Unidades en paquete:

30/100

tipo de receta:

Prescription

Área terapéutica:

FRIBIC ACID DERIVATIVES

Resumen del producto:

Active ingredient group (AIG) number: 0118895001; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2017-07-31

Fitxa tècnica

Page 1 of 38
PRODUCT MONOGRAPH
PR
FENOFIBRATE MICRO
FENOFIBRATE, MICRONIZED FORMULATION
Capsules (200 mg)
LIPID METABOLISM REGULATOR
Sanis Health Inc. Date of revision:
333 Champlain Street, Suite 102 February 13, 2014
Dieppe, New Brunswick
E1A 1P2
Submission Control number: 171447
Page 2 of 38
PRODUCT MONOGRAPH
PR
FENOFIBRATE MICRO
fenofibrate, micronized formulation
THERAPEUTIC CLASSIFICATION
Lipid Metabolism Regulator
ACTIONS AND CLINICAL PHARMACOLOGY
FENOFIBRATE MICRO
(fenofibrate, micronized formulation) lowers elevated serum lipids by
decreasing the low density lipoprotein (LDL) fraction rich in
cholesterol and the very low
density lipoprotein (VLDL) fraction rich in triglycerides. In
addition, fenofibrate increases the
high density lipoprotein (HDL) cholesterol fraction.
Fenofibrate appears to have a greater depressant effect on the VLDL
than on the low density
lipoproteins (LDL). Therapeutic doses of fenofibrate produce
elevations of HDL cholesterol, a
reduction in the content of the low density lipoproteins cholesterol,
and a substantial reduction in
the triglyceride content of VLDL.
The mechanism of action of fenofibrate has not been definitively
established. Work carried out
to date suggests that fenofibrate:
•
enhances the liver elimination of cholesterol as bile salts;
•
inhibits the biosynthesis of triglycerides and enhances the catabolism
of VLDL by
increasing the activity of lipoprotein lipase;
•
has an inhibitory effect on the biosynthesis of cholesterol by
modulating the activity
of HMG-CoA reductase.
Metabolism and Excretion
After oral administration with food, fenofibrate is rapidly hydrolysed
to fenofibric acid, the
active metabolite. In man it is mainly excreted through the kidney.
Half-life is about 20 hours.
In patients with severe renal failure, significant accumulation was
observed with a large increase
in half-life. Therefore, the dose of fenofibrate may need to be
reduced, depending on the rate of
creatinine clearance.
Distribution
Fenofibric acid is extensively bound (> 99 %) to